We can do better to prevent, diagnose, and manage hypertensive disorders of pregnancy

Last Updated on April 13, 2022


Prenatal and postpartum care – as it’s generally practiced in the United States – hasn’t changed much in over 50 years. First developed primarily to diagnose preeclampsia (then called toxemia), prenatal visits include peeing in a cup, weighing mom, and taking her blood pressure, over the course of 12 to 14 prenatal visits, spaced one month apart until the third trimester when visits increase to once a week in the last month. Following delivery, a single postpartum visit at 6 weeks clears mom to resume normal activities and offers birth control (contraceptives). 

Innovations and disruptive technologies in maternity care are desperately needed to better prevent, diagnose, and manage hypertensive disorders of pregnancy. Research, development, and implementation of newer models of care are, in some places, starting to be realized.

A one-week postpartum visit is now recommended as part of recognizing the physical and mental challenges in the “4th trimester” – the three months following delivery, especially important for mothers who experienced any kind of hypertension or medical complications. The 4th Trimester Project has developed several valuable resources that can help providers better serve their postpartum patients.

Aspirin, while far from being a cure-all, may help some women prevent or delay the onset of preeclampsia and is more widely prescribed to those at high or moderate risk.

Group care, telehealth, and connected care are models being tested in various settings to provide more customized prenatal care. Read more about those below, under Glossary. More advanced biomarkers are in development that can predict a woman’s risk of preeclampsia or diagnose it more accurately and earlier than traditional methods. We are active proponents of these innovations in obstetric care on Capitol Hill and elsewhere.

The Preeclampsia Foundation plays an active and vocal role in these innovations. Our goal is to disrupt inadequate healthcare practices, improve the patient experience, and eliminate disparities and health inequities.


Examples of our work

  • PRIME research network, funded by the Preeclampsia Foundation, studied text-based, remote BP monitoring during the postpartum period at three sites across the country.
  • Heart Health 4 Moms (HH4M), a virtual intervention to reduce cardiovascular risk and improve self-efficacy in preeclampsia survivors, and Health After Preeclampsia: Patient and Provider Engagement (HAPPPEN) study, synthesized and reported the experiences of five postpartum clinics. Both were designed to provide specialty care for preeclampsia survivors.
  • The Cuff Kit program, which we quickly mobilized during the COVID-19 pandemic. Telehealth services were not all equipped to provide women with the blood pressure monitors they needed for at-home monitoring.
  • Our biomarkers statement, a call to action to numerous stakeholders, calling for specific and accurate tests to predict and diagnose preeclampsia and related disorders of pregnancy. Add your voice by signing this petition.



Often under the brand name Centering Pregnancy®,  group care allows a patient to meet with a group of other patients with similar due dates to share and learn relevant information, check blood pressure, and address medical and social services needs. The woman has time alone with her maternity care provider to check fetal heart rate and discuss any unique or sensitive issues. This ad hoc community often create bonds that extend beyond delivery and encourage peer support for parenting and newborn issues.

Telehealth allows a patient to meet with her healthcare provider through a phone or video call. The patient checks her own vital signs such as blood pressure and shares this information with her provider. Under the COVID-19 pandemic, we saw a surge in telehealth usage as regulations were loosened and women were either afraid to physically go to hospitals or clinics and providers sought to minimize unnecessary exposure.

Connected care usually means a patient has a reduced number of individual appointments and in between uses remote technology to assess her BP and other vital signs which are often automatically transmits to her provider. A nurse or some system of assessment ensures those data are monitored and appropriate responded to. An example is this program in Louisiana.

Research, development and marketing of biomarkers to predict and diagnose preeclampsia have accelerated in recent years. In the United Kingdom and other areas of the world, commercial tests are already on the market. Utilizing proteomics, metabolomics, and other analytes, molecular biomarkers have the potential to finally define preeclampsia as one or more specific conditions, rather than its current status as a syndrome because of the loose collection of “clues” that makes diagnosis and treatment often ambiguous, even to experts. Sign a petition to advocate for biomarker development and adoption.

Related Articles